Record-breaking Revenue of HK$484.7M and Net Profit of HK$70.9M Pioneering Breakthroughs in Osteoporosis, Medical Aesthetics, and Ophthalmology Markets HONG KONG SAR - EQS Newswire - 27 March 2024 - A fully integrated biopharmaceutical company – Uni-Bio Science Group Limited ("Uni-Bio Science", together with its subsidiaries referred to as the "Group", stock code: 0690.HK), is pleased to announce its annual results for the year ended 31 December 2023 (the "Year"). Key Accomplishments in 2023 During the Year, the Group achieved a spectrum of accomplishments, for both of its marketed products and innovative biologics. The key highlights include:

1. The Group achieved record-breaking revenue, witnessing a 10.1% year-on-year ("YoY") increase to approximately HK$484.7 million. Sales of Pinup^® and GeneTime^® performed well, registered an increase of 15.0% YoY and 9.54% YoY respectively.
2. Profit for the year experienced a remarkable 84.04% YoY surge, reaching approximately HK$70.9 million, attributed to the Group's diligent cost control measures. These results mark a significant milestone for a research-oriented biopharmaceutical company, laying a strong foundation for future expansion amidst the evolving market landscape.
3. The marketing application of the Group' s Bogutai^® (teriparatide injection) was approved by the China National Medical Products Administration ("NMPA"), marking a significant breakthrough for the Group in orthopedic disease treatment and providing patients with expanded options. Bogutai^® represents the Group's fifth marketed product and distinguishes itself as the first domestically produced disposable pre-filled pen teriparatide injection.
4. The Group reached a significant milestone with the successful introduction of Skbrella™ FN, marking its entry into the advanced skincare raw material market. Currently, Skbrella™ FN is in the stage of formula optimization and packaging design, with plans to officially launch a self-owned medical aesthetic brand utilizing Skbrella™ FN in 2024.
5. The Group established its "Biopeptides Innovative Medicine and Advanced Technology R&D Center" in Beijing. This cutting-edge facility integrates the latest advancements in bioinformatics technology, genetic engineering, and oral formulation techniques, marking a transformative era in the biosynthetic polypeptide drug industry.
6. The NMPA's acceptance of the marketing application for Diquafosol Sodium eye drops on 23 January 2024 marks a pivotal step towards its anticipated market approval in the first quarter of 2025. This milestone heralds a new era in the Group's endeavors to diversify its ophthalmology drug portfolio and broaden treatment options for patients suffering from dry eye syndrome.

Annual Results In 2023, the Group recorded a revenue of approximately HK$484.7 million, representing an increase of 10.1 % YoY. The increase in revenue was mainly attributable to the Group's continuous expansion of hospital coverage and applicable patient population through academic seminars and promotions, which were fully recognized by the market and patients. Pinup^® recorded an increase of 15.0% in revenue from approximately HK$215.1 million to approximately HK$247.4 million for the Year. For the Year, revenue generated from GeneTime^® was approximately HK$186.0 million, representing an increase of 9.8% YoY. GeneSoft^® recorded an increase in revenue from approximately HK$38.4 million to approximately HK$41.3 million, representing an increase of 7.6%. In response to fierce market competition, the Group has strategically slowed down its sales efforts and is actively implementing supplier optimization strategies to bolster its cost advantage. Consequently, revenue from Boshutai^® declined from approximately HK$17.4 million to approximately HK$10.4 million, representing a decrease of 40.2%. Gross profit amounted to approximately HK$392.8 million, representing an increase of 17.3 % as compared approximately HK$334.9 million in 2022, and gross profit margin increased by 4.9 percentage points YoY to 81.0%. Other revenue for the Year increased by 57.8% YoY to approximately HK$13.6 million, which was mainly attributable to its growing CMO business. The Group strictly controlled its general and administrative expenses, which only accounted for 9.8% of revenue in 2023 as compared with 10.7% in 2022. The selling and distribution expenses for the Year increased to 49.8% of revenue from 48.0% in 2022, mainly due to the marketing expenses of Pinup^® increased this year and the strategic expansion of sales force in preparation for new product launches. The R&D expenses decreased by 0.6% YoY to approximately HK$35.6 million due to the completion of several clinical tests and the capitalization of related development expenses. In 2023, there was a remarkable surge in profit, soaring from approximately HK$38.5 million in 2022 to approximately...